Article ; Online: In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
Current atherosclerosis reports
2023 Volume 25, Issue 7, Page(s) 381–389
Abstract: Purpose of review: The purpose of this review is to analyze and discuss the most recent data on in hospital prescription of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors in patients with acute coronary syndrome (ACS).: Recent findings: ... ...
Abstract | Purpose of review: The purpose of this review is to analyze and discuss the most recent data on in hospital prescription of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors in patients with acute coronary syndrome (ACS). Recent findings: Recent randomized clinical trials (RTCs) have demonstrated a beneficial effect of monoclonal antibodies (mAb) PCSK9i prescription in patients with ACS on rapid reduction of low-density lipoprotein cholesterol (LDL-C) and on coronary atherosclerosis assessed by intracoronary imaging. Additionally, the safety profile of mAb PCSK9i was confirmed in all RTCs. Available RCTs show the effectiveness and rapid achievement of LDL-C levels according to American College of Cardiology/American Heart Association and European Society of Cardiology guidelines for ACS patients. However, RCTs addressing cardiovascular outcomes of PCSK9i in-hospital initiation in ACS patients are currently ongoing. |
---|---|
MeSH term(s) | United States ; Humans ; Proprotein Convertase 9 ; PCSK9 Inhibitors ; Cholesterol, LDL ; Subtilisin/therapeutic use ; Acute Coronary Syndrome/drug therapy ; Proprotein Convertases/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Anticholesteremic Agents/therapeutic use ; Anticholesteremic Agents/pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use |
Chemical Substances | PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; PCSK9 Inhibitors ; Cholesterol, LDL ; Subtilisin (EC 3.4.21.62) ; Proprotein Convertases (EC 3.4.21.-) ; Antibodies, Monoclonal ; Anticholesteremic Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Language | English |
Publishing date | 2023-05-24 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2057369-8 |
ISSN | 1534-6242 ; 1523-3804 |
ISSN (online) | 1534-6242 |
ISSN | 1523-3804 |
DOI | 10.1007/s11883-023-01112-3 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5534: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.